Views & Analysis Coming of age: Alnylam and the RNAi revolution Alynylam has a crucial two years ahead of it, but it and RNAi could be about to come of age.
News Circassia shares plummet following cat allergy therapy failu... Company said the failure could have implications for its other products under development
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
News FDA asks for more data on Sarepta's muscular dystrophy drug Regulator asks for more data from ongoing trial.
News UK offers meningitis jab to young people after outbreak The UK government has responded to calls to broaden vaccinations for meningitis B, offering the jab to "thousands" of young people this summer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
